Clinical trial · Interventional
FES-PET for Patients Treated on NCI Protocol 8762
Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study Funding no longer available
Summary
Brief summary (as posted)
A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy. This project will assess the ability and usefulness of imaging hormone-receptor status in breast cancer with positron emission tomography (PET) and 6α-\[18F\]fluoro-17β-estradiol (FES), an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES)) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Optional Diagnostic Imaging
- description
- Optional diagnostic imaging FES-PET/CT imaging
- interventionNames
- Drug: Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Primary outcomes (1)
- measure
- FES baseline tumor SUV measurement
- timeFrame
- Up to 36 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have agreed and signed consent to participate in NCI protocol 8762 and be scheduled to receive the first dose of MK-2206 in a minimum of 48 hours and a maximum of 30 days after the FES-PET/CT imaging. Note: Patients need to be on the endocrine agent for at least 1 week prior to the FES-PET/CT imaging. 2. Patients must have measurable disease (defined by RECIST criteria) or the presence of bone lesions if there is no measurable lesion. 3. Patient must be ≥ 18 years of age. 4. Patient must be able to tolerate and have no contraindication to FES-PET/CT imaging. 5. Patient must be able and willing to give informed consent. Exclusion Criteria: 1. Patient must have no other active cancer at the time of study entry. 2. The research FES-PET/CT scan could not be scheduled more than 48 hours before starting therapy with MK-2206. 3. Patient cannot have received treatment for any other malignancy, with the exception of non-melanoma skin cancer, in the past 5 years. 4. Patients scheduled to receive chemotherapy as the primary source of treatment
References
Publications (0)
Data not yet available